At the ESCMID Global conference in Austria, the development of climate-informed infectious disease risk management systems was discussed.

Concerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...

The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency for its single-dose chikungunya vaccine, Ixchiq.

Reveal Genomics and Ona Therapeutics have entered a strategic partnership to expedite the clinical development of ONA-255.

AI tools are faster at drafting clinical trial documents, but human writers remain indispensable for logical reasoning.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. Pfizer has ...

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Roche has secured approval from the EC for Columvi plus GemOx combo to treat adults with R/R diffuse large B-cell lymphoma ...